
Sign up to save your podcasts
Or


CV outcomes in patients with type 2 diabetes, canagliflozin, cardiorespiratory fitness, the value of randomized trials, and the most important paper of 2018 are reviewed in this week's podcast.
By Medscape4.9
862862 ratings
CV outcomes in patients with type 2 diabetes, canagliflozin, cardiorespiratory fitness, the value of randomized trials, and the most important paper of 2018 are reviewed in this week's podcast.

1,869 Listeners

322 Listeners

547 Listeners

707 Listeners

504 Listeners

167 Listeners

14 Listeners

16 Listeners

3,381 Listeners

135 Listeners

1,144 Listeners

65 Listeners

520 Listeners

365 Listeners

60 Listeners

26 Listeners

7 Listeners

265 Listeners

436 Listeners

273 Listeners